Tag:

Amgen

Latest Headlines

Latest Headlines

Lower-cost Praluent dose may be Sanofi's weapon against Amgen's rival PCSK9 med

Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters expected to be a pricey proposition.

Revving up for price war with Amgen, Sanofi plots low-cost starter dose of PCSK9 med

Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters. Drugmakers in the field--including frontrunners Amgen and Sanofi--prepared for that fight. And now, analysts think they've defined the battle lines.

Can AZ salvage brodalumab against next-gen psoriasis field?

The crowded next-gen psoriasis landscape may lose a contender, now that Amgen has bailed out of its brodalumab pact with AstraZeneca. And if the British pharma decides to go it alone, it'll face plenty of contenders--not to mention reports of side effects--that could make building market share an uphill battle.

UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep

A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a shoo-in at the FDA. But late Friday evening, Amgen abruptly said it was pulling out of the long-running collaboration on the high-profile IL-17 program after evaluating the likely commercial impact it would face in light of the suicidal thoughts some patients reported during the studies.

Amgen's PCSK9 contender lines up for first place in the blockbuster EU race

Amgen is likely to come in second in the race to launch new cholesterol treatments in the U.S., but the Big Biotech is leading the charge in Europe, securing a crucial regulatory recommendation that clears the way for approval.

Racing a crowded field, Amgen says migraine drug looks promising in PhII

Amgen says it got the positive data it was looking for from a Phase II study of AMG 334, one of several experimental migraine drugs that share the same target and are in the running to compete against an old generation of drugs on the market.

Court blocks Novartis' biosimilar copy of Amgen's Neupogen

Amgen is none too eager for Novartis to roll out its newly FDA-approved biosimilar version of its blockbuster Neupogen, and for now, it's getting its way: A U.S. appeals court has blocked sales of the copycat while the companies resolve a patent dispute.

Prepping for spendy launches, pharma execs take a hint from Gilead's pricing fight

As payers continue to flex their drug-pricing muscles, it's more important for drugmakers to land on their good sides--especially as companies prepare to roll pricey treatments onto the market. And pharma execs are taking note.

Amgen wins FDA panel nod for T-Vec in melanoma

FDA staffers had their doubts this week heading into an advisory committee meeting on Amgen's dual-acting cancer vaccine/viral therapy, talimogene laherparepvec (T-Vec). But Wednesday afternoon, a combined FDA advisory panel voted overwhelmingly in favor of the candidate.

FDA panel gives a thumbs up to Amgen's T-Vec for melanoma

Amgen's regulatory team for talimogene laherparepvec (T-Vec) was grilled by a group of outside FDA experts who picked up on some major questions regarding the Phase III melanoma study that was used to back its new drug application. A vigorous defense of the drug, though, helped make a winning case for the therapy, which was ultimately supported by all but one member of the panel.